All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide
All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide

PPP1R1B Recombinant Monoclonal Antibody

Datasheet
Code CSB-RA201307A0HU
Size US$210
Order now
Image
  • Western Blot
    Positive WB detected in: COLO-205 whole cell lysate(30µg), Mouse brain tissue lysate(30µg), Rat brain tissue lysate(30µg)
    All lanes: PAP antibody at 1:1000
    Secondary
    Goat polyclonal to rabbit IgG at 1/40000 dilution
    Predicted band size: 23 kDa
    Observed band size: 32 kDa
    Exposure time：30s
  • IHC image of CSB-RA201307A0HU diluted at 1:100 and staining in paraffin-embedded human brain tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Q9UD71
Target Names
PPP1R1B
Alternative Names
Protein phosphatase 1 regulatory subunit 1B (DARPP-32) (Dopamine- and cAMP-regulated neuronal phosphoprotein), PPP1R1B, DARPP32
Species Reactivity
Human, Mouse, Rat
Immunogen
Recombinant Antibody
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Isotype
Rabbit IgG
Clone No.
13B12
Purification Method
Affinity-chromatography
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
Form
Liquid
Tested Applications
ELISA, WB, IHC
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
IHC 1:50-1:200
Protocols
ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Troubleshooting and FAQs
Antibody FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

PPP1R1B, also known as DARPP-32, serves as a critical integrator of dopaminergic and glutamatergic signaling in the central nervous system. This phosphoprotein functions as a potent inhibitor of protein phosphatase 1 when phosphorylated by protein kinase A, positioning it at the convergence of multiple neurotransmitter pathways. Its enrichment in medium spiny neurons of the striatum makes it an essential marker for studying reward circuitry, addiction mechanisms, and neurodegenerative conditions affecting the basal ganglia.

This recombinant monoclonal antibody, generated against a synthetic peptide from human PPP1R1B, offers the reproducibility and sequence-defined consistency that demanding neurological research requires. Because the antibody is produced from a stable clone rather than traditional hybridoma methods, you can expect uniform performance across experiments and between lot numbers, eliminating a common source of variability in longitudinal studies.

Validation testing demonstrates robust detection across species, with Western blot analysis confirming specific bands in COLO-205 whole cell lysate as well as mouse and rat brain tissue lysates. The observed molecular weight of approximately 32 kDa, higher than the predicted 23 kDa, likely reflects post-translational modifications including phosphorylation events central to DARPP-32's regulatory function. This cross-species reactivity between human and rodent samples supports translational research workflows. Immunohistochemistry validation in paraffin-embedded human brain tissue at 1:100 dilution shows clear staining, with recommended working dilutions ranging from 1:50 to 1:200 depending on your specific tissue preparation and detection system.

This antibody supports investigations into dopamine signaling pathways, striatal function, psychiatric disorders, and Parkinson's disease research where DARPP-32 dysregulation plays a documented role.

Usage
For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

PPP1R1B Antibodies

PPP1R1B Proteins

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Inhibitor of protein-phosphatase 1.
Gene References into Functions
  1. t-Darpp phosphorylation at T39 seems to be crucial for t-Darpp-mediated PKA activation and this activation appears to occur through an association with RI and sequestering of RI away from PKAc. The t-Darpp-RI interaction could be a druggable target to reduce PKA activity in drug-resistant cancer. PMID: 28867659
  2. our results lend support for a potential role of DARPP-32 genetic variants in neural response to potential reward triggering cues PMID: 29048604
  3. To facilitate live-cell identification, a human embryonic stem cell line was generated using CRISPR-mediated gene editing at the DARPP32 locus. PMID: 28065797
  4. Study associates polymorphisms in DRD2, DARPP-32, and COMT genes with novel category learning performance. Modeling results suggest that striatal dopaminergic genes influence selective attention processes whereas cortical genes mediate the ability to update complex rule representations. PMID: 26918585
  5. Results show that expression of human DARPP-32 protein isoforms depends on the striatal neurodevelopmental stage with t-DARPP being specific for the human adult striatum. PMID: 27475250
  6. In vivo xenograft models demonstrated that overexpression of DARPP-32 promotes angiogenesis and tumour growth. PMID: 25779598
  7. This study strongly suggests that inflammation-regulated DARPP-32 constitutes a key component of H. pylori-mediated gastric tumourigenesis. PMID: 27590997
  8. This study did not find any statistical difference in the state-anxiety dimension for the rs12601930C/T, rs879606A/G, and rs3764352A/G genotypes, but statistical differences in the trait-anxiety dimension for the rs879606A/G (F = 5.207, P = 0.006) and rs3764352A/G (F = 3.960, P = 0.020) genotype. PMID: 27995567
  9. DARPP-32 is mainly cleaved at Thr(153) by calpain and this cleavage of DARPP-32 reduces CREB phosphorylation via loss of its inhibitory function on PP1; results suggest a novel mechanism of DARPP-32-CREB signalling dysregulation in Alzheimer's disease PMID: 26178297
  10. No significant differences in mRNA expression levels of DRD2 and DARPP-32 were found among controls, patients with psychotic disorder not otherwise specified, and schizophrenia/schizophreniform disorder. PMID: 26561806
  11. Striatal function was indexed by a gene coding for DARPP-32, which is densely expressed in the striatum where it is necessary for synaptic plasticity PMID: 26818509
  12. Findings show that PPP1R1B-STARD3 fusion transcript has a key role in subsets of gastric cancers through the activation of PI3K/AKT signaling. PMID: 24276243
  13. The results of this study found that the mean t-DARPP expression level in the caudate was higher in patients with schizophrenia than in control individuals. PMID: 24704945
  14. Results suggest that variation in PPP1R1B affects the abundance of the splice variant t-DARPP-32 mRNA and may reflect potential molecular mechanisms implicated in schizophrenia and affective disorders PMID: 23295814
  15. The immunostaining was more decreased for DARPP-32 than for the morphological changes of striatal neurons in multiple system atrophy. PMID: 23715974
  16. This study showed that variations in genotypes relevant for DARPP-32 functions are associated more with aging-related impairments in the explicit than the implicit component of sequence learning. PMID: 24035787
  17. density of DARPP-32-immunoreactive (IR) neurons in the II and III layers of the RAIC was significantly decreased (p<0.05) in the schizophrenia group compared with the healthy control group. PMID: 21821092
  18. Bcl-2 and DARPP-32 have roles in regulating inositol 1,4,5-trisphosphate receptor phosphorylation and promoting cell survival PMID: 24395794
  19. High DARPP32/STAT3, DARPP32/STAT5B, and STAT5B/STAT3 ratios were associated with longer patient progression free survival. PMID: 23250732
  20. The present study provides novel evidence for an association between the DARPP-32 gene (SNP rs907094) and attentional control of auditory perception. PMID: 23639477
  21. Findings show a novel mechanism by which DARPP-32 promotes cell invasion by regulating CXCR4-mediated activation of the MT1-MMP/MMP-2 pathway. PMID: 23160836
  22. PPP1R1B rs12601930 was associated with projection and splitting. rs3764352 was associated with splitting. No significant association was found between rs879606 and defenses. PPP1R1B polymorphisms are involved in immature defenses. PMID: 23080070
  23. Our findings support a role for the DRD2 and PPP1R1B genes in conferring risk for autism in families with only affected males and show an additive effect of these genes towards prediction of affected status in our families. PMID: 22559203
  24. Our findings uncover a novel mechanism of TRAIL resistance mediated by DARPP-32, whereby it inhibits the intrinsic apoptosis pathway through upregulation of BCL-xL PMID: 22589394
  25. DARPP32 has a role in pluripotent stem cell differentiation toward medium-sized spiny neurons PMID: 23250204
  26. no significant association of BDNF or DARPP-32 polymorphisms with schizophrenia in Malays. PMID: 22576830
  27. the decrease in DARPP-32 in schizophrenia was more marked in neurons of dorsolateral prefrontal cortex than in other cells or other brain regions PMID: 22179181
  28. DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib. PMID: 21741919
  29. [review] Genetic polymorphisms modulating DARPP-32 mRNA expression and cognition in humans are associated with changes in activation in the entire striatum, and striatal connectivity with frontal cortex, without connection to any other brain region. PMID: 20631684
  30. the DARPP-32-related pathogenesis in schizophrenia may be more severe in the superior temporal gyrus than previously found in the prefrontal cortex PMID: 21453742
  31. Results suggest that polymorphisms in the DARPP-32 gene are involved in the biological mechanisms that confer the traits of novelty seeking and harm avoidance. PMID: 21369787
  32. Findings demonstrate that t-DARPP regulates beta-catenin/TCF activity, thereby implicating a novel oncogenic signaling in upper gastrointestinal cancers. PMID: 21447180
  33. our data suggest: (i) C14ORF28, GNB2L1, MLLT3, DRD2 and DARPP-32 are important in the pathogenesis of schizophrenia and bipolar disorder PMID: 20874815
  34. Findings underscore the potential role of t-DARPP in regulating cell growth and proliferation through PI3 kinase-dependent mechanism. PMID: 20836878
  35. This study did not find DAOA significant associations with schizophrenia. Thus, PPP1R1B genes do not fit the antagonistic pleiotropy PMID: 20483474
  36. The composite expression score, calculated from immunostaining patterns, increased significantly from normal or gastritis to metaplasia, dysplasia, and adenocarcinoma (P < .001). PMID: 20580047
  37. DARPP-32 changes the usage of tra2-beta1 dependent alternative exons in a concentration-dependent manner, suggesting that the DARPP-32:tra2-beta1 interaction is a molecular link between signaling pathways and pre-mRNA processing. PMID: 20074680
  38. t-Darpp and DARPP-32 expression are novel prognostic and predictive biomarkers in breast cancer. PMID: 19301121
  39. DARPP 32 frequently are overexpressed in common subtypes of human adenocarcinomas suggest that these proteins may be important in tumorigenesis. PMID: 14508844
  40. overexpression of DARPP-32 is associated with gastric cancer PMID: 14991576
  41. DARPP-32 expression arises after a phase of dysplasia esophageal squamous cell carcinoma; tumours expressing DARPP-32 progress less rapidly than DARPP-32-negative tumours PMID: 15188007
  42. multiple domains in I-1 target cellular PP1 complexes, and I-1 has a role as a cellular regulator of eIF2alpha phosphorylation PMID: 15345721
  43. Expression of Darpp-32 is associated with a potent antiapoptotic advantage for cancer cells through a p53-independent mechanism that involves preservation of mitochondrial potential and increased Bcl2 levels. PMID: 16061638
  44. Thus, DARPP-32 signaling downstream of DDR1 is a potential new target for effective anti-metastatic breast cancer therapy PMID: 17027969
  45. Potential involvement of PPP1R1B in the etiology of nicotine dependence. PMID: 17171661
  46. DARPP-32 plays a pivotal role in cognitive function and possibly in the pathogenesis of schizophrenia. PMID: 17290303
  47. The up-regulation of ZNRD1 significantly inhibited the drug sensitivity of gastric cancer cells over-expressing DARPP-32, indicating that ZNRD1 may be important in the DARPP-32-mediated MDR of gastric cancer PMID: 17492506
  48. The present study suggests that DARPP-32 decreases in the DLPFC of patients with schizophrenia and bipolar disorder. PMID: 17521792
  49. The results of this study do not preclude the possibility that the PPP1R1B is a susceptibility gene for schizophrenia in the Chinese population. PMID: 17618027
  50. The decreased expression of DARPP-32 in oral premalignant and malignant lesions suggests a tumor suppressor role for this protein in the tumorigenesis of these lesions. PMID: 17695523

Show More

Hide All

Subcellular Location
Cytoplasm.
Protein Families
Protein phosphatase inhibitor 1 family
Database Links

HGNC: 9287

OMIM: 604399

KEGG: hsa:84152

STRING: 9606.ENSP00000254079

UniGene: Hs.286192

Promotions
Reward For Reviews
Free antibody trial
Contact Us

  Email: [email protected]
  Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

Related Articles
Antibody FAQs What Is an Antibody? How to Choose an Antibody for Scientific Research? The difference between primary antibody and secondary antibod The Meaning of Irregular Antibody Screening Tag Antibodies, Your Good Partner in Protein Research How to Choose the Loading Control Antibodies?
Related pathways
cAMP signaling pathway
CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of email
Email
[email protected]
icon of address
Address
No. 269, Shendun 5th Road, Donghu Hi-Tech Development Area, Hubei Province, 430206, P.R.China
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Privacy Policy
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*